Arena Pharmaceuticals has been granted a patent for a method of treating atopic dermatitis by administering a specific compound in a standard dose. The method involves using (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid once daily in an amount equivalent to about 2.0 mg. GlobalData’s report on Arena Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Arena Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arena Pharmaceuticals, was a key innovation area identified from patents. Arena Pharmaceuticals's grant share as of February 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of atopic dermatitis with compound 1

Source: United States Patent and Trademark Office (USPTO). Credit: Arena Pharmaceuticals Inc

A recently granted patent (Publication Number: US11896578B2) discloses a method for treating atopic dermatitis in individuals by administering a specific compound, (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or its pharmaceutically acceptable forms, once daily in a dosage equivalent to about 2.0 mg of Compound 1. The administration can be done orally, with the compound formulated as a capsule or tablet suitable for oral intake.

Furthermore, the patent claims cover various forms of Compound 1, including its calcium salt, L-arginine salt, and anhydrous, non-solvated, crystalline forms. The method outlined in the patent involves the daily administration of Compound 1 or its salts in the specified dosage to effectively treat atopic dermatitis in individuals. The patent emphasizes the oral administration of the compound, making it convenient for patients to adhere to the treatment regimen. Overall, the patent provides a detailed method for utilizing Compound 1 in different forms to address atopic dermatitis, showcasing the potential for this compound in dermatological treatments.

To know more about GlobalData’s detailed insights on Arena Pharmaceuticals, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies